Payment overview · 2025
General Payments
$573.66
23 reported records · 15 companies
Healthcare provider profile · identity verified
Dan N Olson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CORTLAND, OH · NPI 1417981077
Verified facts
What the public records show
CMS Open Payments records show Dan N Olson, M.D. received $573.66 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $118.84 | 20.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.99 | 14.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.09 | 11.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.91 | 10.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.01 | 7.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.79 | 5.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.99 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.11 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.07 | 3.9% | 1 | 2025 |
| QIAGEN, LLC | Unresolved — no canonical attribution shown | $20.80 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.32 | 3.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.60 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.43 | 2.7% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $15.40 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.31 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $573.66 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $124.00 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.09 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $33.79 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 53 |
| Omeprazole | Omeprazole | 178 | 62 |
| Spironolactone | Spironolactone | 159 | 53 |
| Lisinopril | Lisinopril | 152 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 48 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 144 | 41 |
| Metformin Hcl Er | Metformin Hcl | 142 | 44 |
| Gabapentin | Gabapentin | 125 | 45 |
| Valsartan | Valsartan | 114 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 30 |
| Prednisone | Prednisone | 99 | 45 |
| Glimepiride | Glimepiride | 98 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 15 |
| Eliquis | Apixaban | 89 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 14 |
| Ezetimibe | Ezetimibe | 83 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 32 |
| Furosemide | Furosemide | 81 | 34 |
| Allopurinol | Allopurinol | 71 | 20 |
| Tramadol Hcl | Tramadol Hcl | 67 | 14 |
| Losartan Potassium | Losartan Potassium | 65 | 21 |
| Metformin Hcl | Metformin Hcl | 65 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | suppressed |
| Finasteride | Finasteride | 59 | 19 |
| Atenolol | Atenolol | 58 | 18 |
| Lorazepam | Lorazepam | 56 | 21 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 14 |
| Meloxicam | Meloxicam | 50 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 15 |
| Carvedilol | Carvedilol | 46 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 42 | 15 |
| Trazodone Hcl | Trazodone Hcl | 42 | 15 |
| Amoxicillin | Amoxicillin | 37 | 29 |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Montelukast Sodium | Montelukast Sodium | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 23 |
| Mirtazapine | Mirtazapine | 34 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Simvastatin | Simvastatin | 28 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | 11 |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $573.66 · 23 records | ABBVIE INC. | ABRYSVO, AFREZZA, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, INGREZZA, JARDIANCE, NEXLETOL, OTEZLA, PREVNAR 20, REPATHA, REXULTI, VERQUVO, YUPELRI | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error